Skip to main content

Testosterone Use Not Tied to Gynecological Cancers in Transmasculine Individuals

Medically reviewed by Carmen Pope, BPharm. Last updated on May 16, 2025.

By Lori Solomon HealthDay Reporter

FRIDAY, May 16, 2025 -- Short-term testosterone use among transmasculine and gender diverse (TMGD) individuals is not associated with an increased risk for gynecological cancers, according to a study published online May 12 in eClinicalMedicine.

Asra Vestering, M.D., from the Amsterdam University Medical Center, and colleagues evaluated the incidence of gynecological (pre-)malignancies among 1,955 TMGD individuals using testosterone treatment between Feb. 17, 1972, and Dec. 3, 2018.

The researchers found a median duration of testosterone usage of 1.7 years before hysterectomy and oophorectomy (median age, 24 years) and 3.1 years before vaginal and/or vulvar surgery or biopsy (median age, 29 years). No gynecological malignancies were seen, while expected incidence was ≤0.26 for all cancer types. Across samples, one ovarian borderline tumor, one case of simple endometrial hyperplasia, and one case of vulvar intraepithelial neoplasia (VIN) III were detected. The age-adjusted standardized incidence ratio for >VIN2 was 0.23.

"We found no increased risk of these cancers compared to women from the general population. None of these cancers were diagnosed in the entire participant group," Vestering said in a press release. "This is valuable information for both health care providers and transmasculine and gender-diverse people who are considering starting hormone therapy."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer

THURSDAY, June 5, 2025 -- For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel...

Less Than Half of Adults Aware of Link Between Alcohol, Cancer

THURSDAY, June 5, 2025 -- Less than half of U.S. adults are aware of the association between alcohol and cancer, according to a research letter published online May 29 in JAMA...

Physical Activity Linked to Better Survival for Specific Cancer Types

FRIDAY, May 30, 2025 -- Engaging in leisure-time moderate- to vigorous-intensity physical activity (MVPA) is associated with better overall survival for participants with a...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.